• Immunology deals with physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders
• With the new advancement in immune sector- global pharmaceuticals continue to grow in the field despite the disruption during the COVID-19. As in 2019- Abbvie again secured the top position with total revenue of $22.15B- followed by J&J- Roche- and Amgen
• Our team at PharmaShots has compiled a list of top 20 immunology companies based on their 2020 immunology revenue

Antares Pharma is a specialty pharmaceutical company focused primarily on the development & commercialization of pharmaceutical products and technologies addressing the unmet needs in the targeted therapeutic areas. The company has reported a total sale of $0.015B from its immunology segment in 2020 from the sales of Otrexup in RA- pJIA- Psoriasis.

3S Bio is a Chinese Biotechnology company that focuses on oncology- nephrology- dermatology- and auto-immune diseases. The company unveiled the total sales of $0.09B in its immunology segment during the year 2020 from the sales of Yisaipu- which is a TNF a inhibitor indicated to treat RA- AS and psoriasis.

GSK is a global healthcare multinational company involves in the development- manufacture- and marketing of pharmaceutical products- vaccines- OTC medicines- and health-related consumer products. With only approved products- Benlysta- GSK has generated a revenue of $0.99B in 2020. In Dec 2020- the US FDA has approved Benlysta as the first medicine for adult patients with active LN.

Horizon is a biopharmaceutical company that focuses on rare and rheumatic diseases. Horizon has generated the sale of $1.05B from its four approved immunology products including Tepezza- Rayos- Duexis- and Vimovo. During the fiscal year 2020- Tepezza alone has generated $820M revenue- followed by Duexis ($125.3M)- Rayos ($71.8M)- and Vimovo ($37.6M).

Mitsubishi Tanabe Pharma Corporation (MTPC) is a Japanese pharmaceutical company that focuses on diabetes- kidney diseases- autoimmune diseases- and vaccines. The company has reported a total sale of $1.08B from its immunology segment in 2020. In Dec? 2020 MTPC initiates a long-term OLE trial to the phase III MT-1186-A03 trial of edaravone for Amyotrophic lateral sclerosis

Merck & Co. is an American multinational pharmaceutical company. The company develops medicines (oncology- OTC- and generic drugs)- vaccines- biologic therapies- and animal health products. In 2020- Merck-approved drugs including Simponi and Remicade generated revenue of $1.16B.

Astellas is a Japanese multinational pharmaceutical company. It focuses on serving patients? medical needs across multiple therapeutic areas- including cardiology- hematology- immunology- infectious diseases- oncology- and urology. Astellas immune drug- Prograf generated revenue of $1.65B in 2020. In Jan?2020- Astellas announced the construction of a new manufacturing facility for Prograf?s API in the Toyama technology center.

Incyte is a global biopharmaceutical company that focuses on oncology- inflammation- and autoimmune diseases. In 2020- Incyte has generated revenue of $1.93B in its immunology segment. In Jul?2020- Incyte and MorphoSys announced that the FDA approved Monjuvi (tafasitamab-cxix)- which is indicated in combination with lenalidomide for R/R DLBCL

Biogen is a US-based biotechnology company that focuses on developing and delivering innovative therapies globally for neurological- neurodegenerative- and autoimmune diseases. Major areas of it include MS- neuroimmunology- neuromuscular disorders including Spinal Muscular Atrophy (SMA)- movement disorders including Parkinson? disease- Ophthalmology- and neuropsychiatry. Biogen generated a revenue of $1.94 with Tysabri in the immunology segment. In Jun?2020- the company submitted the regulatory filing of Tysabri in the US and the EU.

UCB is a multinational biopharmaceutical company that specializes in two therapeutic areas- the central nervous system (CNS) and immunology. Cimzia has generated total revenue of $2.1B in 2020. In Jan?2020- UCB?s biologic Cimzia (certolizumab pegol) was approved by MHRA for the treatment of PsO- PsA- pustular psoriasis- and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. The approval makes Cimzia the first Fc-free- PEGylated anti-TNF treatment option in Japan.

Eli Lilly is an American pharmaceutical company focused on immunology- neurodegenerative diseases- and endocrinology. Eli Lilly has two approved immunology products including Olumiant and Taltz. Its immune product- Taltz has generated revenue of $1.78B while the remaining is from Olumiant?s sales in 2020. Taltz and Olumiant drove the 37% increase in revenue in Immunology.

BMS is a global biopharmaceutical company that focuses on multiple therapeutic areas including oncology- hematology- cardiovascular- and immunology. Its immune drug- Orencia generated revenue of $3.16 in 2020. The revenue of Orencia increased by 6% and 7% in the US and international market due to higher demand respectively. In Jun?2020- the company reported results of an open-label P-IV Early AMPLE biomarker study assessing the differences by which Orencia and adalimumab interfere with disease progression in the mod. to sev. RA patients.

Takeda is a Japanese multinational biopharmaceutical company. It is one of the top 20 largest pharmaceutical companies in the world by revenue. The company is focused on metabolic disorders- gastroenterology- neurology- inflammation- as well as oncology through its independent subsidiary. With Takeda?s immunology-approved drugs including Immunoglobulin and Albumin- Takeda has generated a $3.56B sale in 2020.

Pfizer is an American multinational pharmaceutical company. Pfizer develops and produces medicines and vaccines for immunology- oncology- cardiology- endocrinology- and neurology. Pfizer?s immune drug- Xeljanz generated revenue of $2.43B- followed by Enbrel ($1.35B) and inflectra ($0.65B) in 2020. In Sept?2020- the US FDA approved Xeljanz (tofacitinib) for the treatment of children and adolescents aged=2yrs. with active pcJIA.

Sanofi is a French multinational pharmaceutical company. The company covers seven major therapeutic areas; cardiovascular- central nervous system- diabetes- internal medicine- oncology- thrombosis- and vaccines. Dupixent and Kevzara together contributed to the $4.60B revenue of the company in the immunology segment.  In November 2020- Dupixent (dupilumab) was approved by European Commission as the first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis.

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel- Switzerland. It is one of the largest pharmaceutical companies in the world. The company is focused on immunology- Hepatology- Dermatology- oncology- Neurology- and Ophthalmology. Novartis? immune drug- Cosentyx generated revenue of $3.9B and Ilaris generated 0.87B in 2020. Cosentyx received approval and launched in the EU and US for nr-axSpA- its fourth major indication- and in August became the first treatment approved in Japan for this indication. In April- Cosentyx also became the first IL17A inhibitor approved in China for the treatment of AS. In June- Ilaris was granted a new indication in the US for active Still?s disease including Adult-Onset Still?s Disease (AOSD).

Amgen is an American multinational biopharmaceutical company that focuses on CV disease- oncology- bone health- neuroscience- immunology- nephrology- and inflammation. In 2020- Enbrel- a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis generated total sales of $4.9B whereas Otezla which is a PDE4 inhibitor generated a revenue of $2.1B.

Roche is a Swiss multinational healthcare company. The immunology department of the company focuses on rheumatoid arthritis (RA)- systemic juvenile idiopathic arthritis- polyarticular juvenile idiopathic arthritis- and giant cell arteritis. Roche?s immunotherapies include Actemra- Xolair- Esbriet- MabThera- Pulmozyme- CellCept- and others.  Actemra produces the highest revenue among all with $3.23B.

Johnson and Johnson is an American multinational company that focuses on multiple therapeutic areas including Cardiovascular & Metabolism- Immunology- Infectious Diseases & Vaccines- Neuroscience- Oncology- and Pulmonary Hypertension. In its immunology segment- J&J focuses on core diseases like rheumatoid arthritis- inflammatory bowel diseases- and psoriasis. In 2020- its leading immunology product- Stelara generated sales of $7.70B- followed by Remicade- Simponi- and Tremfya with the revenue of $3.74B- $2.24B- and $1.34B respectively.

Abbvie is an American Biopharmaceutical company focused on the development of products in immunology- oncology- virology and neuroscience- dermatology. In Dec?2020- Abbvie announced that CHMP recommended the approval of Rinvoq for the expanded use in two additional rheumatic indications: the treatment of adult patients with active psoriatic arthritis and adult